Nyxoah (NYXH) Stock Price & Analysis

155 Followers

NYXH Stock Chart & Stats

$0.90$0.01(6.39%)

At close: Nov 10 4:00 PM EST

Day’s Range: $0.86 - $0.90
52-Week Range: $0.80 - $5.92
Previous Close: $0.85
Volume: N/A
Average Volume (3M): 218.77K
Market Cap: $89.06M
Enterprise Value: $100.05M
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): $0
Price to Earnings (P/E): ―
Beta: 1.38
Next Earnings: Mar 25, 2027 (Est.)
EPS Estimate: -0.2
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Nyxoah News

Nyxoah Earnings Call Highlights Growth and Guidance Reset

Nyxoah Sa (($BE:NYXH)) has held its Q3 earnings call. Read on for the main highlights of the call. Nyxoah’s earnings call carried a clearly positive tone, led by rapid revenue

5d agoNYXH 5YI

Nyxoah reports Q3 EPS (EUR 0.18), consensus (EUR 0.32)

Reports Q3 revenue EUR 9.17M, consensus EUR 9.56M. “We delivered 29% sequential U.S. revenue growth in the third quarter, an acceleration from 22% in the second quarter. Momentum is building

6d agoNYXH 5YI

Nyxoah backs FY26 revenue view EUR 33M-EUR 35M, consensus EUR 34.77M

The company said, “The Company expects gross margin for the full year 2026 to be in the range of 60% to 62%.” Published first on TheFly – the ultimate source

6d agoNYXH 5YI

Nyxoah Reports Strong U.S. Growth and Seeks Broader Genio Indication

Nyxoah ( ($NYXH) ) has issued an update. Nyxoah, a medical technology company developing neuromodulation treatments for obstructive sleep apnea, reported third-quarter global net revenue of €9.2 million, up 19%

6d agoNYXH 5YI

Nyxoah price target lowered to $3 from $6 at Cantor Fitzgerald

Cantor Fitzgerald analyst Sarah James lowered the firm’s price target on Nyxoah (NYXH) to $3 from $6 and keeps an Overweight rating on the shares. Nyxoah lowered its 2026 revenue

2w agoNYXH 5YI

Nyxoah Sets Date for Q3 2026 Results as Genio Sleep Apnea Therapy Scales Globally

Nyxoah ( ($NYXH) ) has issued an update. Nyxoah, a dual-listed Belgian medtech company on Euronext Brussels and Nasdaq, focuses on innovative neuromodulation solutions for obstructive sleep apnea, anchored by

2w agoNYXH 5YI

Nyxoah Cuts 2026 Revenue Guidance as U.S. Sales and CCC Data Drive Q3 Surge

An update from Nyxoah ( ($NYXH) ) is now available. Nyxoah reported preliminary, unaudited results for the third quarter of 2026 on October 19, highlighting global net revenue of about

3w ago6K NYXH

Nyxoah Cuts 2026 Revenue Guidance as U.S. Genio Sales Accelerate

An update from Nyxoah ( ($NYXH) ) is now available. Nyxoah reported preliminary third-quarter 2026 global net revenue of €9.2 million, up 19% sequentially, driven by U.S. net revenue of

3w agoNYXH 5YI

Morning Movers: Cleveland-Cliffs surges following third quarter earnings report

Nasdaq futures are rebounding as technology shares recover from last week’s steep selloff and investors prepare for a busy stretch of third quarter earnings. The rebound follows the Nasdaq and

3w agoCLF EQPT

Nyxoah reports preliminary Q3 revenue EUR 9.2M, consensus EUR 9.93M

“We delivered 29% sequential revenue growth in the U.S. in the third quarter, and our International business performed in line with our expectations. While we are disappointed to adjust our

3w agoNYXH 5YI

Nyxoah cuts FY26 revenue view to EUR 33M-EUR 35M from EUR 36M-EUR 40M

Consensus EUR 37.27M. The company said, “The Company now expects global net revenue for the full year 2026 to be in the range of EUR 33 million to EUR 35

3w agoNYXH 5YI

Nyxoah’s Genio Device Shows Strong 12-Month Results in U.S. Sleep Apnea Trial

An update from Nyxoah ( ($NYXH) ) is now available. Nyxoah reported full 12-month results from its U.S. pivotal ACCCESS study evaluating the Genio hypoglossal nerve stimulation system in obstructive

3w agoNYXH 5YI

Nyxoah presents complete ACCCESS U.S. study data, submits PMA supplement to FDA

Nyxoah (NYXH) announced that the complete 12-month results of the ACCCESS U.S. pivotal study were presented at the International Surgical Sleep Society, or ISSS, annual meeting, taking place October 15-16,

3w agoNYXH 5YI

Nyxoah Taps Former Teleflex Chief Liam Kelly to Lead U.S.-Focused Growth Drive

An announcement from Nyxoah ( ($NYXH) ) is now available. Nyxoah has appointed Liam Kelly as Chief Executive Officer, effective October 1, 2026, replacing Olivier Taelman as the company pivots

1M agoNYXH 5YI

NYXH FAQ

What was Nyxoah’s price range in the past 12 months?

Nyxoah lowest stock price was $0.80 and its highest was $5.92 in the past 12 months.

What is Nyxoah’s market cap?

Nyxoah’s market cap is $89.06M.

When is Nyxoah’s upcoming earnings report date?

Nyxoah’s next earnings report is estimated for Mar 25, 2027 (not yet confirmed), which is in 133 days.

How were Nyxoah’s earnings last quarter?

Nyxoah released its earnings results on Nov 05, 2026. The company reported -$0.198 earnings per share for the quarter, beating the consensus estimate of -$0.346 by $0.149.

Is Nyxoah overvalued?

According to Wall Street analysts Nyxoah’s price is currently Undervalued.

Does Nyxoah pay dividends?

Nyxoah does not currently pay dividends.

What is Nyxoah’s EPS estimate?

Nyxoah’s EPS estimate is -0.20.

How many shares outstanding does Nyxoah have?

Nyxoah has 101,840,220 shares outstanding.

What happened to Nyxoah’s price movement after its last earnings report?

Nyxoah reported an EPS of -$0.198 in its last earnings report, beating expectations of -$0.346. Following the earnings report the stock price went up 4.192%.

Which hedge fund is a major shareholder of Nyxoah?

Hedge funds hold Nyxoah shares: the largest hedge-fund position in Nyxoah is 70,141,757 shares, and hedge funds increased their holdings by 533.9K shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Nyxoah Stock Smart Score

Underperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah (NYXH) Earnings & Revenues

Historic Earnings Reports

NYXH Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call was predominantly positive, supported by 365% year-over-year global revenue growth, accelerating U.S. sequential growth, expanding surgeon and account adoption, international growth, improved gross margin, positive clinical results, and progress toward a potential CCC indication expansion. The main negative factors were the reduction in full-year 2026 revenue guidance, the sequential decline in cash and financial assets, the continuing operating loss, and the need to manage the commercial ramp. Highlights significantly outweighed lowlights.

View all NYXH earnings summaries

NYXH Stock 12 Month Forecast

Average Price Target

$2.25▲(150.28% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

High$3.00

Average$2.25

Low$1.50

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	5	6	10
Technical Analysis	1	6	2
Moving Averages	4	0	8

Technical Analysis >

Similar Stocks

Stocks similar to NYXH
Company	Price & Change	Follow
IRTCIrhythm Technologies
INSPInspire Medical Systems
SENSSenseonics Holdings
STXSStereotaxis
NVCRNovoCure
SNNSmith & Nephew Snats

Compare NYXH Stocks >

Ownership Overview

0.07% Mutual Funds
16.42% Other Institutional Investors
83.51% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

NYXH Stock Chart & Stats

Nyxoah News

Nyxoah Earnings Call Highlights Growth and Guidance Reset

Nyxoah reports Q3 EPS (EUR 0.18), consensus (EUR 0.32)

Nyxoah backs FY26 revenue view EUR 33M-EUR 35M, consensus EUR 34.77M

Nyxoah Reports Strong U.S. Growth and Seeks Broader Genio Indication

Nyxoah price target lowered to $3 from $6 at Cantor Fitzgerald

Nyxoah Sets Date for Q3 2026 Results as Genio Sleep Apnea Therapy Scales Globally

Nyxoah Cuts 2026 Revenue Guidance as U.S. Sales and CCC Data Drive Q3 Surge

Nyxoah Cuts 2026 Revenue Guidance as U.S. Genio Sales Accelerate

Morning Movers: Cleveland-Cliffs surges following third quarter earnings report

Nyxoah reports preliminary Q3 revenue EUR 9.2M, consensus EUR 9.93M

Nyxoah cuts FY26 revenue view to EUR 33M-EUR 35M from EUR 36M-EUR 40M

Nyxoah’s Genio Device Shows Strong 12-Month Results in U.S. Sleep Apnea Trial

Nyxoah presents complete ACCCESS U.S. study data, submits PMA supplement to FDA

Nyxoah Taps Former Teleflex Chief Liam Kelly to Lead U.S.-Focused Growth Drive

NYXH FAQ

Nyxoah Stock Smart Score

Company Description

Nyxoah

Nyxoah (NYXH) Earnings & Revenues

NYXH Earnings Call

Earnings Call Sentiment|Positive

NYXH Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive